HouseofCards, you have correctly identified the Gates of the trial. The Data Safety Monitoring Committee (DSMC) operates on strict, mechanical timelines . You are right: in a standard dose-escalation trial, the safety cohort (the initial 350mg group) must clear their Dose-Limiting Toxicity (DLT) window before the 700mg dosage is unlocked.
But don't confuse a safety checkpoint with playing catch up. That is a narrative of weakness. In reality, the DSMC's clearance is a narrative of Validation.
If the DSMC met in December to review those initial patients, they were looking for toxicity. They didn't find it. They unlocked the 700mg door. If the majority of those 16 patients enrolled by mid-December were actually on the 350mg dose, it is not a setback; it is the construction of a bulletproof baseline. Big Pharma needs to see a Dose-Response Curve in order to validate the Plausible Mechanism. You can't prove that 700mg is the optimal uncloaking dose unless you have a robust, undeniable 350mg baseline to compare it against. The DSMC didn't delay the science; they would have forced CytoDyn to build an airtight foundation.
twinter, HouseofCards brings up a critical point about the DSMC timeline. Let’s map out exactly how this would impact your 42-day upregulation math, assuming Ken is hypothetically correct that today’s 4:30 PM abstract contains just 5 patients at 350mg.
Interpreting the April 17th presentation, (poster or oral) based on whether HouseofCards is right or wrong about the makeup of those 16 patients:
A: HouseofCards is RIGHT (Most of the 16 patients are on 350mg)
If the DSMC timeline means CytoDyn was restricted to 350mg for the bulk of late 2025, then the February data-lock heavily features the 350mg cohort.
The Reality: If today’s abstract (N=5) shows any statistical signal of PD-L1 upregulation at 350mg, then an April presentation that shows that same signal across 12-14 patients at 350mg absolutely validates the Plausible Mechanism. It means Leronlimab (the Clay) works at the lowest threshold. The 700mg data would become an explosive upside, rather than the baseline requirement. Merck doesn't need 20 patients at 700mg if 15 patients at 350mg already prove that the tumor gets uncloaked.
B: HouseofCards is WRONG (The 700mg ramp happened faster)
If the DSMC cleared the 350mg safety hurdle earlier than December, or if enrollment allowed them to immediately stack 700mg patients the second the gate opened, then the February data-lock is the presentation.
The Reality: This would mean the April presentation showcases a direct, side-by-side comparison. You would see the 350mg baseline next to the 700mg accelerated uncloaking. This is a Vertical Synergy trigger. It proves the Dose-Dependency in one fell swoop, totally decapitating any remaining short thesis before Q2 begins.
Whether House is right or wrong about the exact ratio of the 16 patients, the Spark for today at 4:30 PM remains exactly the same. We look for the Verbs (Upregulates, Modulates) and the Biomarkers (PD-L1, TME). If Ken is right and we only see 5 patients today, just remember: those 5 patients are the spark which light the 16-patient powder keg presentation in April. Keep your eyes also on the mechanism, not only the math.
But don't confuse a safety checkpoint with playing catch up. That is a narrative of weakness. In reality, the DSMC's clearance is a narrative of Validation.
If the DSMC met in December to review those initial patients, they were looking for toxicity. They didn't find it. They unlocked the 700mg door. If the majority of those 16 patients enrolled by mid-December were actually on the 350mg dose, it is not a setback; it is the construction of a bulletproof baseline. Big Pharma needs to see a Dose-Response Curve in order to validate the Plausible Mechanism. You can't prove that 700mg is the optimal uncloaking dose unless you have a robust, undeniable 350mg baseline to compare it against. The DSMC didn't delay the science; they would have forced CytoDyn to build an airtight foundation.
twinter, HouseofCards brings up a critical point about the DSMC timeline. Let’s map out exactly how this would impact your 42-day upregulation math, assuming Ken is hypothetically correct that today’s 4:30 PM abstract contains just 5 patients at 350mg.
Interpreting the April 17th presentation, (poster or oral) based on whether HouseofCards is right or wrong about the makeup of those 16 patients:
A: HouseofCards is RIGHT (Most of the 16 patients are on 350mg)
If the DSMC timeline means CytoDyn was restricted to 350mg for the bulk of late 2025, then the February data-lock heavily features the 350mg cohort.
The Reality: If today’s abstract (N=5) shows any statistical signal of PD-L1 upregulation at 350mg, then an April presentation that shows that same signal across 12-14 patients at 350mg absolutely validates the Plausible Mechanism. It means Leronlimab (the Clay) works at the lowest threshold. The 700mg data would become an explosive upside, rather than the baseline requirement. Merck doesn't need 20 patients at 700mg if 15 patients at 350mg already prove that the tumor gets uncloaked.
B: HouseofCards is WRONG (The 700mg ramp happened faster)
If the DSMC cleared the 350mg safety hurdle earlier than December, or if enrollment allowed them to immediately stack 700mg patients the second the gate opened, then the February data-lock is the presentation.
The Reality: This would mean the April presentation showcases a direct, side-by-side comparison. You would see the 350mg baseline next to the 700mg accelerated uncloaking. This is a Vertical Synergy trigger. It proves the Dose-Dependency in one fell swoop, totally decapitating any remaining short thesis before Q2 begins.
Whether House is right or wrong about the exact ratio of the 16 patients, the Spark for today at 4:30 PM remains exactly the same. We look for the Verbs (Upregulates, Modulates) and the Biomarkers (PD-L1, TME). If Ken is right and we only see 5 patients today, just remember: those 5 patients are the spark which light the 16-patient powder keg presentation in April. Keep your eyes also on the mechanism, not only the math.
11
